Bihi Pharmaceuticals is a privately held pharmaceutical company headquartered in Dubai, operating with a focused licensing and partnership model. We work with qualified manufacturing partners and regional distributors to bring reliable, compliant, and market-ready pharmaceutical products to patients. Our approach prioritizes: Strategic product selection Strong regulatory alignment Long-term distributor partnerships
Founder & Chief Executive Officer: Abdirizak Bihi, MD
He is a medical doctor based in Sweden with a background in ophthalmology and more than eight years of experience within clinical medicine and healthcare systems. His professional background informs the company’s focus on regulatory discipline, quality assurance, and structured market entry.
The company was established to address persistent challenges related to access, quality, and regulatory reliability in markets where essential medicines remain inconsistently available despite clear public health needs. The company’s strategic focus on regulatory discipline, quality assurance, and structured market entry reflects his clinical background and long-term perspective on sustainable access to essential medicines.
Bihi Pharmaceuticals operates with a deliberately disciplined and structured approach. The company prioritizes regulatory integrity, manufacturing quality, and sustainable commercialization over rapid expansion or speculative growth.
Strategic decisions are guided by clinical relevance, alignment with national treatment guidelines, and feasibility within existing regulatory frameworks. This ensures that development and market-entry activities remain both responsible and executable.
The company operates through a partner-driven model, collaborating with WHO-GMP compliant manufacturing partners and selected local distributors. This model enables Bihi Pharmaceuticals to maintain high quality standards while remaining operationally efficient.
Manufacturing, regulatory activities, and commercialization are coordinated through clearly defined processes designed to ensure consistency, compliance, and long-term reliability of supply.
All products are manufactured through qualified WHO-GMP compliant partners. Quality oversight and documentation standards are aligned with international regulatory expectations.
Registration strategies are developed with a focus on regulatory clarity, dossier quality, and alignment with local authority requirements.
Market entry is executed through structured frameworks designed to support sustainable distribution, compliance, and continuity of supply.
Bihi Pharmaceuticals maintains a focused geographic and product strategy. Initial market activities are directed toward selected African markets where regulatory pathways are defined and public health demand for essential medicines is well established.
The company deliberately limits portfolio breadth and geographic expansion in early stages to ensure operational control, regulatory consistency, and effective partner oversight.
Engagements with manufacturing partners, distributors, consultants, and other stakeholders are conducted through defined governance processes. These include NDA-based discussions, clear role definitions, and structured collaboration frameworks.
This governance approach ensures transparency, alignment of expectations, and long-term sustainability across all partnerships.